FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: chalcopyrite

Sort
E.g., 2013-05-23
E.g., 2013-05-23
Enter a comma separated list of user names.

Caribou Coffee Company, Inc. (NASDAQ:CBOU) the second largest company-owned premium coffeehouse operator in the United States based on the number of coffeehouses, reported financial results for the fourth quarter and fiscal year 2010 (periods ended January 2, 2011) and confirmed fiscal 2011 guidance.

AM Castle & Co. (NYSE:CAS) a global distributor of specialty metal and plastic products, services and supply-chain solutions, announced that it will release fourth quarter and full-year results for the period ended December 31, 2010 on Tuesday, March 8, 2011. Management will hold a conference call at 11:00 a.m.

USEC Inc. (NYSE:USU) reported on the progress of ongoing negotiations with the Department of Energy’s (DOE) Loan Guarantee Program office on a term sheet for a conditional commitment for the financing of the American Centrifuge Plant.

USEC and other companies have news this afternoon. To read moe great articles, go to: http://doubleinstocks.com/?p=14169

LeapFrog Enterprises Inc. (NYSE:LF) announced LeapPad Explorer™, a multifunctional learning tablet that ushers in the next generation of learning, digital reading and personal creativity for children ages four and up, available beginning summer 2011 in global English markets.

There is more news on LeapFrog and it's award winning products, please visit: http://doubleinstocks.com/?p=14165

Hansen Medical, Inc. (NASDAQ:HNSN), the global leader in flexible robotics and the developer of robotic technology for accurate 3D control of catheter movement, announced that it will release its financial and operating results for the fourth quarter and full year ended December 31, 2010 after market close on Wednesday, February 23, 2011.

Magellan Petroleum Corporation (NASDAQ:MPET) reported a consolidated net loss of $2.1 million ($.04 per share) on total revenue of $4.5 million for its fiscal second quarter ended December 31, 2010, as compared to a net loss of $3.4 million ($.06 per share) on gross revenues of $3.7 million in the immediately prior quarter.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) an emerging specialty pharmaceutical company, announced that additional safety data are being highlighted from its Phase 3 trial of EXPAREL™ (bupivacaine extended-release liposome injection) in bunionectomy. The data showed comparable safety in wound healing and significantly improved efficacy in pain reduction compared to placebo.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) an emerging specialty pharmaceutical company, announced that additional safety data are being highlighted from its Phase 3 trial of EXPAREL™ (bupivacaine extended-release liposome injection) in bunionectomy. The data showed comparable safety in wound healing and significantly improved efficacy in pain reduction compared to placebo.

Pages

ADVERTISE WITH US